KetamineOne Capital Limited (“Ketamine One” or the
“Company”) (NEO: MEDI) (OTC: KONEF) (FRA: 6FC), a company
focused on consolidating medical clinics and becoming a North
American leader in mental health treatments, is pleased to announce
that it has entered into a telehealth and virtual health
partnership to increase accessibility and service offerings to its
patients (the “
Telehealth Strategy”). In order to
better address the needs of patients as well as incorporate the
Telehealth Strategy across its portfolio of mental health clinics,
contract research capabilities and its focus on digital
therapeutics, the Company has launched a patient-facing website at
www.ketamine.one/patients/home (the “
New
Website”).
The New Website offers visitors the ability to
find a clinic location, obtain a referral form, and learn more
about ketamine, the Company’s process, and treatments for various
conditions, among other information. To create awareness about its
new Telehealth Strategy, the Company is also in the process of
creating social media profiles on various platforms under the “K1
Integrative Care” brand and similar iterations, which will also
have a patient focus like the New Website. Additionally, the
Company’s main corporate website at www.ketamine.one has been
updated with more information about itself, KGK Science and the
Company’s technology-focused mission, as well as other updates for
investors.
Virtual Platform With
iHealthOX
In a groundbreaking agreement for a
ketamine-based clinic network, the Company has partnered with
iHealthOX to provide patients with a customized digital tool
specifically for mental health. Initially focused on Ketamine One’s
Canadian clinic network, patients will have access to live coaching
sessions, options for one-on-one therapy, evidence-based
educational material, and 24/7 emergency support. The iHealthOX
platform will be available to patients in both desktop and mobile
versions, thereby extending the Company’s services beyond its
clinic locations.
Through iHealthOX’s online services, patients
now have an option to be virtually assessed by a physician and a
clinical health provider to determine their suitability to undergo
ketamine therapy and ketamine-enhanced psychotherapy. The patient
care plan also includes access to proven cognitive behavioral
therapy techniques and coursework, a personal care coach who will
create an individual care plan that will teach patients the skills
they need to build resilience and healthy routines. iHealthOX also
provides live therapist and coach-led group sessions that helps
participants collectively learn, share, and heal around topics
critical to their mental well-being. In addition to one-on-one
therapy offerings, participants will also be able to choose from a
number of condition-specific virtual programs including, but not
limited to, managing depression, controlling anxiety, reducing
stress, mindfulness and meditation, and improving sleep.
Management Commentary
“This arrangement with iHealthOX is
groundbreaking for ketamine and emerging therapies. Patients will
have support available on a 24/7 basis and will also have direct
access to licensed therapists and other tools purposely designed to
address their individual needs,” said Adam Deffett, Interim CEO of
Ketamine One. “This agreement also allows Ketamine One to engage
primary care teams throughout the treatment process, while at the
same time providing emergency support. I believe this opens up a
new treatment model that is more approachable and can reach more
people in need of help,” added Mr. Deffett.
“We look forward to our new partnership with
Ketamine One and being able to provide much needed mental health
services to more patients across Canada and the United States,”
said Terri Storey, Co-Founder and CEO, iHealthOX.
“There is a growing need for mental health care
services across North America,” added Matthew Segal, Co-Founder,
iHealthOX, and CEO, Charlie Wellbeing. “Through our virtual care
model, we can play a key role in helping Ketamine One provide more
personalized and integrated health care experiences for their
growing number of patients across North America.”
Optimized Clinic Network
Recent changes to regulations as a result of the
COVID-19 pandemic have resulted in a greater number of healthcare
services being performed virtually. Accordingly, and together with
Ketamine One’s new Telehealth Strategy, many of the Company’s
acquired clinics are now serving patients virtually rather than
in-person at physical clinic locations. As a result, the Company is
accelerating the rebranding and realignment of its clinic portfolio
with a focus on breakthrough mental healthcare and veteran-focused
clinics.
The Company’s network of clinics currently
consists of multiple brands including IRP Health, Canabo and
MindScape, with more locations and brands being added both
organically and by acquisition in the near future, including but
not limited to the previously announced letters of intent to
acquire NY Ketamine Medical Practice PLLC and TriStar Wellness LLC,
and in partnership with Veteran Services USA.
To better pursue Ketamine One’s mission, the
Company has identified certain legacy locations to be well
positioned for the IRP Health brand and to serve veterans. After a
detailed review of the Company’s entire clinic portfolio, including
an assessment of each clinic’s physical space and lease terms,
Ketamine One has transitioned multiple locations to a virtual care
model in order to optimize its clinic portfolio.
In summary, there are currently nine clinics
operated by Ketamine One that are serving patients on an in-person
basis, with the remainder of the former clinic locations continuing
to serve patients on a virtual basis. The Company is actively
seeking new locations that are well suited to offer both mental
health treatments and be utilized for research through Ketamine
One’s wholly owned contract research organization, KGK Science.
ABOUT iHEALTHOX
iHealthOX is a health and wellness benefits
company for employers that uses data and advanced technologies to
turn health care expenses into high value investments. Through its
holistic and proactive approach, iHealthOX uses personalized care
plans and online services to reduce absenteeism and increases
employee productivity. iHealthOX was founded by CEO Terri Storey,
whose 20 years’ experience in Canada’s mental health care and tech
sectors includes creating one of the largest mental health
treatment organizations in Ontario and developing the first
algorithms to instantly match mental health patients with health
care providers. For more information, please visit
www.ihealthox.com.
ABOUT KETAMINE ONE
KetamineOne Capital Limited is a company focused
on consolidating medical clinics and becoming a North American
leader in mental health treatments. It is working to provide the
critical infrastructure needed to develop and deliver breakthrough
mental health treatments. Currently, Ketamine One has a network of
clinics across North America, with plans to further consolidate the
highly fragmented industry. The recent addition of KGK Science Inc.
as the Company’s contract research division also places the company
at the forefront of premium clinical research based on its
extensive experience in pharmaceuticals, cannabis, and the emerging
psychedelic medicine industries. As a collective enterprise,
Ketamine One is dedicated to helping solve the growing need for
safe and accessible mental health therapy.
On behalf of:
KETAMINE ONE
"Adam Deffett"Adam Deffett, Interim CEO
For further information, please contact:
Nick Kuzyk, Investor RelationsTel:
1-844-PHONE-K1 (1-844-746-6351)Email: IR@ketamine.one Web:
www.ketamine.one Twitter: @KetamineOne
Notice Regarding Forward-Looking
Information:
This news release contains forward-looking
statements including but not limited to statements regarding the
Company’s business, assets or investments, as well as other
statements that are not historical facts. Readers are cautioned not
to place undue reliance on forward-looking statements, as there can
be no assurance that the plans, intentions or expectations upon
which they are based will occur. By their nature, forward-looking
statements involve numerous assumptions, known and unknown risks
and uncertainties, both general and specific, that contribute to
the possibility that the predictions, forecasts, projections and
other forward-looking statements will not occur, which may cause
actual performance and results in future periods to differ
materially from any estimates or projections of future performance
or results expressed or implied by such forward-looking statements.
These assumptions, risks and uncertainties include, among other
things, the state of the economy in general and capital markets in
particular, investor interest in the business and future prospects
of the Company.
The forward-looking statements contained in this
news release are made as of the date of this news release. Except
as required by law, the Company disclaims any intention and assumes
no obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable securities law. Additionally, the
Company undertakes no obligation to comment on the expectations of,
or statements made, by third parties in respect of the matters
discussed above.
Myconic Capital (TSXV:MEDI)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Myconic Capital (TSXV:MEDI)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024